Quarterly ResultAug 6, 2026, 07:12 AM
Cullinan Therapeutics Q2 Net Loss $53.7M; Cash Runway into 2029
AI Summary
Cullinan Therapeutics reported its second quarter 2026 financial results, with cash and investments totaling $356.0 million, extending its cash runway into 2029. The company's net loss for the quarter decreased to $53.7 million from $70.1 million in the prior year, driven by reduced R&D expenses. Cullinan also provided significant pipeline updates, including upcoming multi-dose regimen data for CLN-978 and Velinotamig in autoimmune diseases, and the initiation of a potentially registrational Phase 2 study for CLN-049 in relapsed/refractory AML in Q3 2026. Additionally, the NDA for zipalertinib was accepted by the US FDA with a PDUFA date in February 2027.
Key Highlights
- Cash and investments were $356.0 million as of June 30, 2026, providing runway into 2029.
- Net loss for Q2 2026 was $53.7 million, down from $70.1 million in Q2 2025.
- R&D expenses decreased to $44.4 million in Q2 2026 from $61.0 million in Q2 2025.
- CLN-978 multi-dose regimen data in RA expected in Q3 2026, SLE in Q4 2026.
- Velinotamig multi-dose regimen data in SLE expected in Q4 2026.
- CLN-049 potentially registrational Phase 2 study in R/R AML to begin in Q3 2026.
- Zipalertinib NDA accepted by US FDA with PDUFA target action date of February 27, 2027.
Price Impact
More from CGEM